ICER assessment of treatment-resistant depression and synthetic psilocybin from COMPASS Pathways

The supplied metadata identifies an ICER assessment focused on treatment-resistant depression, with synthetic psilocybin from COMPASS Pathways listed as an intervention of interest. The available material provides no clinical results, comparative effectiveness findings, economic analysis, safety outcomes, or conclusions about the intervention. It also includes an email contact for questions. The metadata description refers to an analysis of ifezuntrigene inilparvovec for Huntington's disease, which does not align with the title or the listed psilocybin intervention, so the scope and relevance of that description are uncertain. The supplied publication date is October 21, 2026.